15,089 Shares in TG Therapeutics, Inc. $TGTX Acquired by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. acquired a new position in TG Therapeutics, Inc. (NASDAQ:TGTX) during the second quarter, HoldingsChannel.com reports. The fund acquired 15,089 shares of the biopharmaceutical company’s stock, valued at approximately $543,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC lifted its stake in TG Therapeutics by 54.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 23,775 shares of the biopharmaceutical company’s stock valued at $898,000 after buying an additional 8,338 shares during the period. New York State Teachers Retirement System lifted its stake in TG Therapeutics by 175.0% in the first quarter. New York State Teachers Retirement System now owns 120,364 shares of the biopharmaceutical company’s stock valued at $4,746,000 after buying an additional 76,600 shares during the period. Crossmark Global Holdings Inc. acquired a new position in TG Therapeutics in the first quarter valued at approximately $226,000. GAMMA Investing LLC lifted its stake in TG Therapeutics by 77.7% in the first quarter. GAMMA Investing LLC now owns 4,543 shares of the biopharmaceutical company’s stock valued at $179,000 after buying an additional 1,986 shares during the period. Finally, Strs Ohio acquired a new position in TG Therapeutics in the first quarter valued at approximately $785,000. 58.58% of the stock is owned by institutional investors and hedge funds.

Insider Activity at TG Therapeutics

In other news, Director Sagar Lonial sold 20,852 shares of the company’s stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total transaction of $672,268.48. Following the transaction, the director owned 94,061 shares of the company’s stock, valued at $3,032,526.64. This represents a 18.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 10.64% of the stock is owned by corporate insiders.

TG Therapeutics Trading Up 0.3%

Shares of TG Therapeutics stock opened at $35.22 on Wednesday. The stock has a fifty day simple moving average of $32.52 and a 200 day simple moving average of $35.00. TG Therapeutics, Inc. has a 12-month low of $22.61 and a 12-month high of $46.48. The company has a market capitalization of $5.59 billion, a P/E ratio of 95.19 and a beta of 1.97. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.15). TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The business had revenue of $141.15 million during the quarter, compared to analysts’ expectations of $147.76 million. During the same period in the prior year, the firm posted $0.04 EPS. The firm’s revenue for the quarter was up 92.1% on a year-over-year basis. TG Therapeutics has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on TGTX shares. Weiss Ratings reissued a “hold (c-)” rating on shares of TG Therapeutics in a research note on Wednesday, October 8th. B. Riley boosted their price target on TG Therapeutics from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, September 17th. The Goldman Sachs Group upgraded TG Therapeutics to a “hold” rating and set a $37.00 price objective for the company in a report on Thursday, July 10th. Finally, HC Wainwright initiated coverage on TG Therapeutics in a report on Monday, October 6th. They set a “buy” rating and a $60.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.00.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.